# A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

> **NCT04137289** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 110 (actual)

## Conditions studied

- Gastrointestinal Neoplasms
- Cholangiocarcinoma
- Pancreatic Neoplasms

## Interventions

- **DRUG:** BI 905711

## Key facts

- **NCT ID:** NCT04137289
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-11
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-11-27
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04137289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04137289, "A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04137289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*